한글목차

X 염색체 연쇄성 저인산혈증의 동향 및 예측

세계의 X 염색체 연쇄성 저인산혈증 시장은 2024년부터 2030년까지 연평균 복합 성장률(CAGR) 9.5%로 성장할 것으로 예측됩니다. 이 시장의 주요 촉진요인은 XLH 사례 증가와 유전성 질환의 연구 개발에 대한 투자 증가입니다. 세계의 X 염색체 연쇄성 저인산혈증 시장의 미래는 병원 및 클리닉 시장 및 연구센터 시장에서의 기회에 의해 유망시되고 있습니다.

부문별 X 염색체 연쇄성 저인산혈증

본 조사는 세계 X 염색체 연쇄성 저인산혈증의 치료별, 최종 용도별 및 지역별 예측을 포함합니다.

X 염색체 연쇄성 저인산혈증 시장 인사이트

Lucintel의 예측에 따르면 예측 기간 동안 약물이 더 높은 성장을 이룰 전망입니다.

이 시장에서는 예측 기간 동안 연구센터가 더 큰 부문을 유지할 것으로 보입니다.

북미는 예측 기간 동안 가장 규모가 큰 지역이 될 것입니다.

FAQ

Q1. 시장 성장 예측은 :

A1. 세계의 X 염색체 연쇄성 저인산혈증 시장은 2024년부터 2030년까지 연평균 복합 성장률(CAGR) 9.5%로 성장할 것으로 예측됩니다.

Q2. 시장 성장에 영향을 미치는 주요 촉진요인은 :

A2. 이 시장의 주요 촉진요인은 XLH 사례 수 증가와 유전성 질환 연구 개발에 대한 투자 증가입니다.

Q3. 시장의 주요 부문은 :

A3. X 염색체 연쇄성 저인산혈증 시장의 미래는 병원 및 클리닉 시장 및 연구센터 시장에서의 기회에 의해 유망할 것입니다.

Q4. 시장의 주요 기업은 :

A4. 주요 X 염색체 연쇄성 저인산혈증 기업은 다음과 같습니다:

• Ultragenyx Pharmaceutical
• Validus Pharmaceuticals
• ProSpec-Tany Technogene
• Merck
• Zeria Pharmaceutical
• Smith & Nephew
• Narang Medical

Q5. 향후 가장 큰 시장 부문은 :

A5. Lucintel은 약이 예측 기간 동안 높은 성장을 이룰 것으로 예상했습니다.

Q6. 시장에서 향후 5년간 최대가 될 것으로 예상되는 지역은 :

A6. 예측기간 동안 북미가 가장 규모가 큰 지역으로 유지할 것으로 예상됩니다.

Q7. 보고서 사용자 정의는 가능한가?

A7. 그렇습니다, Lucintel는 추가 비용 없이 10% 주문을 받아서 만듭니다.

목차

제1장 주요 요약

제2장 세계의 X 염색체 연쇄성 저인산혈증 시장 : 시장 역학

• 서문, 배경, 분류
• 공급망
• 업계의 촉진요인 및 과제

제3장 시장 동향 및 예측 분석(2018-2030년)

• 거시경제 동향(2018-2023년) 및 예측(2024-2030년)
• 세계의 X염색체 연쇄성 저인혈증 시장 동향(2018-2023년) 및 예측(2024-2030년)
• 세계의 X 염색체 연쇄성 저인산혈증 시장 : 치료별
  • 약
  • 외과적 및 정형외과적 치료
• 세계의 X 염색체 연쇄성 저인산혈증 시장 : 최종 용도별
  • 병원 및 클리닉
  • 연구센터
  • 기타

제4장 시장 동향 및 예측 분석(2018-2023년) : 지역별

• 지역별 세계의 X 염색체 연쇄성 저인산혈증 시장
• 북미의 X 염색체 연쇄성 저인산혈증 시장
• 유럽의 X 염색체 연쇄성 저인산혈증 시장
• 아시아태평양의 X 염색체 연쇄성 저인산혈증 시장
• 기타 지역의 X 염색체 연쇄성 저인산혈증 시장

제5장 경쟁 분석

• 제품 포트폴리오 분석
• 업무 통합
• Porter's Five Forces 분석

제6장 성장 기회 및 전략 분석

• 성장 기회 분석
• 세계 X 염색체 연쇄성 저인산혈증 시장의 새로운 동향
• 전략 분석
  • 신제품 개발
  • 세계 X 염색체 연쇄성 저인산혈증 시장의 능력 확대
  • 세계 X 염색체 연쇄성 저인산혈증 시장에서의 합병, 인수 및 합작 사업
  • 인증 및 라이선싱

제7장 주요 기업의 기업 프로파일

• Ultragenyx Pharmaceutical
• Validus Pharmaceuticals
• ProSpec-Tany Technogene
• Merck
• Zeria Pharmaceutical
• Smith & Nephew
• Narang Medical

영문목차

X-Linked Hypophosphatemia Trends and Forecast

The future of the global x-linked hypophosphatemia market looks promising with opportunities in the hospital & clinic and research center markets. The global x-linked hypophosphatemia market is expected to grow with a CAGR of 9.5% from 2024 to 2030. The major drivers for this market are growing numbers of XLH cases and increasing investment in genetic disease research & development.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

X-Linked Hypophosphatemia by Segment

The study includes a forecast for the global x-linked hypophosphatemia by treatment, end use, and region.

X-Linked Hypophosphatemia Market by Treatment [Shipment Analysis by Value from 2018 to 2030]:

• Medication
• Surgical/Orthopedic Treatment

X-Linked Hypophosphatemia Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

• Hospitals & Clinics
• Research Centers
• Others

X-Linked Hypophosphatemia Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of X-Linked Hypophosphatemia Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies x-linked hypophosphatemia companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the x-linked hypophosphatemia companies profiled in this report include-

• Ultragenyx Pharmaceutical
• Validus Pharmaceuticals
• ProSpec-Tany Technogene
• Merck
• Zeria Pharmaceutical
• Smith & Nephew
• Narang Medical

X-Linked Hypophosphatemia Market Insights

Lucintel forecasts that medication is expected to witness higher growth over the forecast period.

Within this market, research center will remain larger segment over the forecast period.

North America will remain the largest region over the forecast period.

Features of the Global X-Linked Hypophosphatemia Market

Market Size Estimates: X-linked hypophosphatemia market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: X-linked hypophosphatemia market size by treatment, end use, and region in terms of value ($B).

Regional Analysis: X-linked hypophosphatemia market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different treatments, end uses, and regions for the x-linked hypophosphatemia market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the x-linked hypophosphatemia market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the growth forecast for x-linked hypophosphatemia market?

Answer: The global x-linked hypophosphatemia market is expected to grow with a CAGR of 9.5% from 2024 to 2030.

Q2. What are the major drivers influencing the growth of the x-linked hypophosphatemia market?

Answer: The major drivers for this market are growing numbers of XLH cases and increasing investment in genetic disease research & development.

Q3. What are the major segments for x-linked hypophosphatemia market?

Answer: The future of the x-linked hypophosphatemia market looks promising with opportunities in the hospital & clinic and research center markets.

Q4. Who are the key x-linked hypophosphatemia market companies?

Answer: Some of the key x-linked hypophosphatemia companies are as follows:

• Ultragenyx Pharmaceutical
• Validus Pharmaceuticals
• ProSpec-Tany Technogene
• Merck
• Zeria Pharmaceutical
• Smith & Nephew
• Narang Medical

Q5. Which x-linked hypophosphatemia market segment will be the largest in future?

Answer: Lucintel forecasts that medication is expected to witness higher growth over the forecast period.

Q6. In x-linked hypophosphatemia market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period.

Q7. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the x-linked hypophosphatemia market by treatment (medication and surgical/orthopedic treatment), end use (hospitals & clinics, research centers, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global X-Linked Hypophosphatemia Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global X-Linked Hypophosphatemia Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global X-Linked Hypophosphatemia Market by Treatment
  • 3.3.1: Medication
  • 3.3.2: Surgical/Orthopedic Treatment
• 3.4: Global X-Linked Hypophosphatemia Market by End Use
  • 3.4.1: Hospitals & Clinics
  • 3.4.2: Research Centers
  • 3.4.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global X-Linked Hypophosphatemia Market by Region
• 4.2: North American X-Linked Hypophosphatemia Market
  • 4.2.1: North American X-Linked Hypophosphatemia Market by Treatment: Medication and Surgical/Orthopedic Treatment
  • 4.2.2: North American X-Linked Hypophosphatemia Market by End Use: Hospitals & Clinics, Research Centers, and Others
• 4.3: European X-Linked Hypophosphatemia Market
  • 4.3.1: European X-Linked Hypophosphatemia Market by Treatment: Medication and Surgical/Orthopedic Treatment
  • 4.3.2: European X-Linked Hypophosphatemia Market by End Use: Hospitals & Clinics, Research Centers, and Others
• 4.4: APAC X-Linked Hypophosphatemia Market
  • 4.4.1: APAC X-Linked Hypophosphatemia Market by Treatment: Medication and Surgical/Orthopedic Treatment
  • 4.4.2: APAC X-Linked Hypophosphatemia Market by End Use: Hospitals & Clinics, Research Centers, and Others
• 4.5: ROW X-Linked Hypophosphatemia Market
  • 4.5.1: ROW X-Linked Hypophosphatemia Market by Treatment: Medication and Surgical/Orthopedic Treatment
  • 4.5.2: ROW X-Linked Hypophosphatemia Market by End Use: Hospitals & Clinics, Research Centers, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global X-Linked Hypophosphatemia Market by Treatment
  • 6.1.2: Growth Opportunities for the Global X-Linked Hypophosphatemia Market by End Use
  • 6.1.3: Growth Opportunities for the Global X-Linked Hypophosphatemia Market by Region
• 6.2: Emerging Trends in the Global X-Linked Hypophosphatemia Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global X-Linked Hypophosphatemia Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global X-Linked Hypophosphatemia Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Ultragenyx Pharmaceutical
• 7.2: Validus Pharmaceuticals
• 7.3: ProSpec-Tany Technogene
• 7.4: Merck
• 7.5: Zeria Pharmaceutical
• 7.6: Smith & Nephew
• 7.7: Narang Medical